Trial Profile
An open label study to evaluate the safety and effect on disease progression of triple combination treatment with erlotinib (Tarceva), bevacizumab (Avastin), and capecitabine (Xeloda) in patients with locally advanced and/or metastatic pancreatic cancer (REBECA-Trial)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Jul 2018
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Erlotinib (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms REBECA
- Sponsors Roche
- 12 Jul 2018 Results published in the Investigational New Drugs
- 23 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 May 2013 Planned End Date changed from 1 Dec 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.